Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting
Brief Summary: The purpose of this study is to compare the effects of anti-HIV drug courses of different lengths in infants who became HIV infected at birth.


Options:
A: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
B: Intervention Type: DRUG; Name: nevirapine; Assigned to Arm(s): N/A
C: Arm Label: Deferred therapy Arm; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Early therapy for 40 weeks; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Early therapy for 96 weeks; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Intervention Type: DRUG; Name: Abacavir sulfate; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks
D: Arm Label: Coh I: NVP; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Coh I: LPV/r; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Lopinavir/ritonavir, Drug: Zidovudine | Arm Label: Coh II: NVP; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Coh II: LPV/r; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Lopinavir/ritonavir, Drug: Zidovudine | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): Coh I: LPV/r, Coh I: NVP, Coh II: LPV/r, Coh II: NVP | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): Coh I: LPV/r, Coh II: LPV/r | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Coh I: NVP, Coh II: NVP | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): Coh I: LPV/r, Coh I: NVP, Coh II: LPV/r, Coh II: NVP

Answer: C